ReviewHeliyon2023
COVID-19 and tuberculosis coinfection: An overview of case reports/case series and meta-analysis of prevalence studies.
Review in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Retractions in tuberculosis research: analyzing patterns, reasons, and temporal trends from 1993 to 2023.Archives of microbiology · 2026Article
- Prevalence and determinants of tuberculosis and COVID-19 among patients with presumptive tuberculosis in a Nigerian tertiary hospital.BMC infectious diseases · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Article
- Right atrial thrombus and pulmonary embolism in a young adult with COVID‑19 and tuberculosis coinfection: a case report.Thrombosis journal · 2025Article
- Antifungal, Antimycobacterial, Protease and α‒Amylase Inhibitory Activities of a Novel Serine Bifunctional Protease Inhibitor from Adenanthera pavonina L. Seeds.Probiotics and antimicrobial proteins · 2025Article
- Comparative Insights into COVID-19 and Tuberculosis: Clinical Manifestations, Inflammatory Markers, and Outcomes in Pulmonary Versus Extrapulmonary Tuberculosis andJournal of clinical medicine · 2025Article
- Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.Infectious medicine · 2025Article
- Prospects and Research Trends of Tuberculosis in Iran: A Bibliometric Study With a Science Mapping Approach.Interdisciplinary perspectives on infectious diseases · 2025Article
- Impact of COVID-19 pandemic responses on tuberculosis incidence: insights from Shantou, China.BMC public health · 2024Article
- Colliding Challenges: An Analysis of SARS-CoV-2 Infection in Patients with Pulmonary Tuberculosis versus SARS-CoV-2 Infection Alone.Medicina (Kaunas, Lithuania) · 2024Article
- Spatio-Temporal Pattern of Tuberculosis Distribution in Romania and Particulate Matter Pollution Associated With Risk of Infection.GeoHealth · 2024Article
- Protective interplay:Frontiers in immunology · 2024Article
- Synthesis and Biological Activity of Piperidinothiosemicarbazones Derived from Aminoazinecarbonitriles.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Emergence of Pulmonary Tuberculosis While Recovering From COVID-19 Pneumonia: A Case Report.Cureus · 2023Article
- Clinical manifestations of active tuberculosis patients coinfected with severe acute respiratory syndrome coronavirus-2.Journal of clinical tuberculosis and other mycobacterial diseases · 2023Article
- Tuberculosis and COVID-19 in the elderly: factors driving a higher burden of disease.Frontiers in immunology · 2023Review
- Immune interaction between SARS-CoV-2 andFrontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Coronavirus disease 2019 (COVID-19) coinfection with other respiratory pathogens poses a serious concern that can complicate diagnosis, treatment, and prognosis. Since COVID-19 and tuberculosis are both severe respiratory infections, their symptoms may overlap and even increase mortality in case of coinfection. The current study aimed to investigate the coinfection of tuberculosis and COVID-19 worldwide through a systematic review and meta-analysis. Methods: A systematic literature search based on the Systematic Reviews and Meta-Analyses" (PRISMA) was performed on September 28, 2021, for original research articles published in PubMed, Web of Science, and Embase databases from December 2019 to September 2021 using relevant keywords. Data analysis was performed using Stata 14 software. Results: The final evaluation included 18 prevalence studies with 5843 patients with COVID-19 and 101 patients with COVID-19 and Conclusion: COVID-19 has a low prevalence of tuberculosis coinfection, but it remains a critical issue, especially for high-risk individuals. The exact rate of simultaneous tuberculosis in COVID-19 patients could not be reported since we didn't have access to all data worldwide. Therefore, further studies in this field are strongly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.